https://orcid.org/0000-0002-1881-3670
References
- Hultcrantz M, Kristinsson SY, Andersson TM-L, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995–3001.
- Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016;174(3):382–396.
- Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069.
- Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35(9):2592–2601.
- Abu-Zeinah G, Silver RT, Abu-Zeinah K, et al. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2021;36:1–4.
- Barbui T, Masciulli A, Carobbio A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (low-PV study): a multicentre, randomised phase 2 trial. Artic Lancet Haematol. 2021;8:175–184.
- Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017;123(14):2680–2687.
- Abu-Zeinah K, Saadeh K, Silver RT, et al. Excess mortality in young patients with myeloproliferative neoplasms. Blood. 2021;138(Suppl. 1):235.
- Dores GM, Curtis RE, Linet MS, et al. Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001–2017. Am J Hematol. 2021;96(12):E451–E454.